Introduction: Tumor protein P53, also known as p53, cellular tumor antigen p53, is any isoform of a protein encoded by homologous genes in various organisms, such as TP53 (humans) and Trp53 (mice). This homolog (originally thought to be, and often spoken of as, a single protein) is crucial in vertebrates, where it prevents cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation.
Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
Cyclophosphamide, also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. It is taken by mouth or injection into a vein.
In this descriptive-analytical study, we investigate carboplatin and cyclophosphamide effects on P53 protein using molecular docking method.
Methods: In this study, we used pubchem.ncbi.nlm.nih.gov, www.drugbank.com,and www.uniprot.org to examine carboplatin and cyclophosphamide. Also software ViewerLite, AutoDockTools-1.5.6, Chimera 1.15 and PyRx were used.
Results: After performing molecular docking separately for carboplatin and cyclophosphamide, we found that conformation1 of carboplatin with negative binding affinity and RMSD had a better effect on P53 protein.
Conclusion: According to docking studies, we found that carboplatin had a better effect on P53 protein to induce apoptosis and prevent cancer cell growth.